Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2795)	6/28/2010 6:02:32 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

OREX continued to bounce up from the $4 level. <g> It was up 18.07% during regular trading and is still doing OK AHs. The stock opened with a small UG. Volume of 5,477,664 was > 2.5x its ADV bigcharts.marketwatch.com On Saturday it announced results from a 24-week open-label study demonstrating that treatment with Contrave resulted in significant improvements in depressive symptoms that was accompanied by weight loss and improved control of eating in overweight and obese patients with major depression.<g> As mentioned, the ACTAY is $13.50 OREX has a good amount of cash left, but has been burning its cash at a good rate.<g> The insiders hold > 40%. OREX has already submitted an NDA for Contrave and there were no major side effects reported in the PIII Will keep a TT at $6 But ready to increase it on further good news.<g> bigcharts.marketwatch.com Bernard